Predictive Factors And Long-Term Visual Outcomes After Anti-Vascular Endothelial Growth Factor Treatment Of Retinal Angiomatous Proliferation

References

• Yannuzzi LA, Negrao S, Iida T, et al. Retinal angiomatous proliferation in age-related macular degeneration. Retina. 2001;21:416–434. doi:10.1097/00006982-200110000-00003
   PubMed Web of Science ®Google Scholar
• Viola F, Massacesi A, Orzalesi N, Ratiglia R, Staurenghi G. Retinal angiomatous proliferation: natural history and progression of visual loss. Retina. 2009;29:732–739. doi:10.1097/IAE.0b013e3181a395cb
   Web of Science ®Google Scholar
• Bottoni F, Massacesi A, Cigada M, et al. Treatment of retinal angiomatous proliferation in age-related macular degeneration: a series of 104 cases of retinal angiomatous proliferation. Arch Ophthalmol. 2005;123:1644–1650. doi:10.1001/archopht.123.12.1644
   PubMed Web of Science ®Google Scholar
• Johnson TM, Glaser BM. Focal laser ablation of retinal angiomatous proliferation. Retina. 2006;26:765–772. doi:10.1097/01.iae.0000244264.98642.af
   Web of Science ®Google Scholar
• Boscia F, Furino C, Sborgia L, Reibaldi M, Sborgia C. Photodynamic therapy for retinal angiomatous proliferations and pigment epithelium detachment. Am J Ophthalmol. 2004;138:1077–1079. doi:10.1016/j.ajo.2004.06.072
   Web of Science ®Google Scholar
• Boscia F, Parodi MB, Furino C, Reibaldi M, Sborgia C. Photodynamic therapy with verteporfin for retinal angiomatous proliferation. Graefes Arch Clin Exp Ophthalmol. 2006;244:1224–1232. doi:10.1007/s00417-005-0205-2
   PubMed Web of Science ®Google Scholar
• Sakimoto S, Gomi F, Sakaguchi H, Tano Y. Recurrent retinal angiomatous proliferation after surgical ablation. Am J Ophthalmol. 2005;139:917–918. doi:10.1016/j.ajo.2004.10.046
   Web of Science ®Google Scholar
• Shiragami C, Iida T, Nagayama D, Baba T, Shiraga F. Recurrence after surgical ablation for retinal angiomatous proliferation. Retina. 2007;27:198–203. doi:10.1097/01.iae.0000224938.61915.f0
   Web of Science ®Google Scholar
• Kuroiwa S, Arai J, Gaun S, Iida T, Yoshimura N. Rapidly progressive scar formation after transpupillary thermotherapy in retinal angiomatous proliferation. Retina. 2003;23:417–420. doi:10.1097/00006982-200306000-00027
   Web of Science ®Google Scholar
• Engelbert M, Zweifel SA, Freund KB. “Treat and extend” dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization/retinal angiomatous proliferation. Retina. 2009;29:1424–1431. doi:10.1097/IAE.0b013e3181bfbd46
   PubMed Web of Science ®Google Scholar
• Atmani K, Voigt M, Le Tien V, et al. Ranibizumab for retinal angiomatous proliferation in age-related macular degeneration. Eye (Lond). 2010;24:1193–1198. doi:10.1038/eye.2010.9
   Web of Science ®Google Scholar
• Matsumoto H, Sato T, Morimoto M, et al. Treat-and-extend regimen with aflibercept for retinal angiomatous proliferation. Retina. 2016;36:2282–2289. doi:10.1097/IAE.0000000000001104
   PubMed Web of Science ®Google Scholar
• Inoue M, Arakawa A, Yamane S, Kadonosono K. Long-term results of intravitreal ranibizumab for the treatment of retinal angiomatous proliferation and utility of an advanced RPE analysis performed using spectral-domain optical coherence tomography. Br J Ophthalmol. 2014;98:956–960. doi:10.1136/bjophthalmol-2013-304251
   PubMed Web of Science ®Google Scholar
• McBain VA, Kumari R, Townend J, Lois N. Geographic atrophy in retinal angiomatous proliferation. Retina. 2011;31:1043–1052. doi:10.1097/IAE.0b013e3181fe54c7
   PubMed Web of Science ®Google Scholar
• Berg K, Roald AB, Navaratnam J, Bragadottir R. An 8-year follow-up of anti-vascular endothelial growth factor treatment with a treat-and-extend modality for neovascular age-related macular degeneration. Acta Ophthalmol (Copenh). 2017;95:796–802. doi:10.1111/aos.13522
   PubMed Web of Science ®Google Scholar
• Lee JH, Lee MY, Lee WK, Hartnett ME. Incidence and risk factors of massive subretinal hemorrhage in retinal angiomatous proliferation. PLoS One. 2017;12:e0186272. doi:10.1371/journal.pone.0186272
   PubMed Web of Science ®Google Scholar
• Daniel E, Shaffer J, Ying GS, et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). Ophthalmology. 2016;123:609–616. doi:10.1016/j.ophtha.2015.10.034
   PubMed Web of Science ®Google Scholar
• Cho HJ, Lee TG, Han SY, et al. Long-term visual outcome and prognostic factors of intravitreal anti-vascular endothelial growth factor treatment for retinal angiomatous proliferation. Graefes Arch Clin Exp Ophthalmol. 2016;254:23–30. doi:10.1007/s00417-015-2993-3
   Web of Science ®Google Scholar
• Bhisitkul RB, Mendes TS, Rofagha S, et al. Macular atrophy progression and 7-year vision outcomes in subjects from the ANCHOR, MARINA, and HORIZON studies: the SEVEN-UP study. Am J Ophthalmol. 2015;159:915–24 e2. doi:10.1016/j.ajo.2015.01.032
   PubMed Web of Science ®Google Scholar
• Baek J, Lee JH, Kim JY, Kim NH, Lee WK. Geographic atrophy and activity of neovascularization in retinal angiomatous proliferation. Invest Ophthalmol Vis Sci. 2016;57:1500–1505. doi:10.1167/iovs.15-18837
   Web of Science ®Google Scholar
• Jaffe GJ, Martin DF, Toth CA, et al. Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2013;120:1860–1870. doi:10.1016/j.ophtha.2013.01.073
   PubMed Web of Science ®Google Scholar
• Chae B, Su D, Gal-Or O, Freund KB, Sarraf D. Type 3 neovascularisation: long-term analysis of visual acuity and optical coherence tomography anatomical outcomes. Br J Opthalmol. 2019;103:43–48. doi:10.1136/bjophthalmol-2018-311850
   Web of Science ®Google Scholar
• Grunwald JE, Daniel E, Huang J, et al. Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2014;121:150–161. doi:10.1016/j.ophtha.2013.08.015
   PubMed Web of Science ®Google Scholar
• Grunwald JE, Pistilli M, Daniel E, et al. Incidence and growth of geographic atrophy during 5 years of comparison of age-related macular degeneration treatments trials. Ophthalmology. 2017;124:97–104. doi:10.1016/j.ophtha.2016.09.012
   PubMed Web of Science ®Google Scholar